Jin X H, Siragy H M, Carey R M
Department of Medicine, University of Virginia, School of Medicine, Charlottesville, USA.
Hypertension. 2001 Sep;38(3):309-16. doi: 10.1161/01.hyp.38.3.309.
The objective of this study was to test the hypothesis that renal interstitial (RI) cGMP is natriuretic in vivo. In conscious rats (n=8), urinary sodium excretion (U(Na)V) was significantly greater on days 3 and 4 of RI infusion of cGMP (1.17+/-0.14 and 1.61+/-0.11 mmol/24 h, respectively) than during vehicle infusion (0.56+/-0.15 and 0.70+/-0.17 mmol/24 h, respectively) (P<0.01). Similarly, U(Na)V was greater on days 3 and 4 of RI infusion of 8-bromo-cGMP (2.15+/-0.42 and 2.16+/-0.1 mmol/24 h, respectively). Protein kinase G inhibitor Rp-8-pCPT-cGMPS reduced cGMP-induced and 8-bromo-cGMP-induced U(Na)V to control levels. Acute RI infusion of L-arginine (L-Arg, 40 mg. kg(-1). min(-1)), but not D-arginine, caused an increase in U(Na)V from 1.65+/-0.11 to 4.07+/-0.1 micromol/30 min (P<0.01). This increase was blocked by RI infusion of N(G)-nitro-L-arginine methyl ester (100 ng. kg(-1). min(-1)) by the phosphodiesterase (PDE II) activator 5,6DMcBIMP (0.01 micromol/microL), by PDE II (0.03 U. kg(-1). min(-1)) itself, or by the soluble guanylyl cyclase inhibitor 1-H-[1,2,4]oxadiazolo-[4,2-alpha]quinoxalin-1-one (ODQ, 0.12 mg. kg(-1). min(-1)). The PDE II activator also blocked L-Arg-stimulated cGMP levels. The NO donor S-nitroso-N-acetylpenicillamine (SNAP, 0.12 micromol. L(-1). kg(-1). min(-1)) increased U(Na)V from 1.65+/-0.11 to 2.93+/-0.08 micromol/30 min (P<0.01), and this response was blocked completely by ODQ. Renal arterial but not RI administration of the heat-stable enterotoxin of Escherichia coli induced natriuresis. RA infusion of cGMP (3 microg/min) increased U(Na)V, renal blood flow (RBF), and glomerular filtration rate (GFR). Renal cortical interstitial cGMP infusion increased U(Na)V with no effect on total RBF, renal cortical blood flow, or GFR. Similarly, the natriuretic actions of renal interstitial L-Arg or SNAP were not accompanied by any change in RBF or GFR. Medullary cGMP infusion had no effect on U(Na)V, total RBF, or medullary blood flow. Texas red-labeled cGMP infused via the RI space was distributed exclusively to cortical renal tubular cells. The results demonstrate that RI cGMP inhibits renal tubular sodium absorption via protein kinase G independently of hemodynamic changes. These observations indicate that the cortical interstitial compartment provides a potentially important domain for cell-to-cell signaling within the kidney.
本研究的目的是检验肾间质(RI)cGMP在体内具有利钠作用这一假说。在清醒大鼠(n = 8)中,RI输注cGMP的第3天和第4天尿钠排泄量(U(Na)V)(分别为1.17±0.14和1.61±0.11 mmol/24 h)显著高于输注溶媒时(分别为0.56±0.15和0.70±0.17 mmol/24 h)(P<0.01)。同样,RI输注8-溴-cGMP的第3天和第4天U(Na)V也较高(分别为2.15±0.42和2.16±0.1 mmol/24 h)。蛋白激酶G抑制剂Rp-8-pCPT-cGMPS将cGMP诱导的和8-溴-cGMP诱导的U(Na)V降至对照水平。RI急性输注L-精氨酸(L-Arg,40 mg·kg⁻¹·min⁻¹)而非D-精氨酸,使U(Na)V从1.65±0.11增加至4.07±0.1 μmol/30 min(P<0.01)。这种增加被RI输注N(G)-硝基-L-精氨酸甲酯(100 ng·kg⁻¹·min⁻¹)、磷酸二酯酶(PDE II)激活剂5,6-二甲基苯并咪唑啉酮(0.01 μmol/μL)、PDE II本身(0.03 U·kg⁻¹·min⁻¹)或可溶性鸟苷酸环化酶抑制剂1-H-[1,2,4]恶二唑并-[4,2-α]喹喔啉-1-酮(ODQ,0.12 mg·kg⁻¹·min⁻¹)所阻断。PDE II激活剂也阻断L-Arg刺激的cGMP水平。一氧化氮供体S-亚硝基-N-乙酰青霉胺(SNAP,0.12 μmol·L⁻¹·kg⁻¹·min⁻¹)使U(Na)V从1.65±0.11增加至2.93±0.08 μmol/30 min(P<0.01),且该反应被ODQ完全阻断。肾动脉而非RI给予大肠杆菌热稳定肠毒素可诱导利钠作用。肾动脉输注cGMP(3 μg/min)增加U(Na)V、肾血流量(RBF)和肾小球滤过率(GFR)。肾皮质间质输注cGMP增加U(Na)V,对总RBF、肾皮质血流量或GFR无影响。同样,肾间质L-Arg或SNAP的利钠作用未伴随RBF或GFR的任何变化。髓质输注cGMP对U(Na)V、总RBF或髓质血流量无影响。经RI间隙输注的德克萨斯红标记cGMP仅分布于肾皮质肾小管细胞。结果表明,RI cGMP通过蛋白激酶G抑制肾小管钠重吸收,且不依赖于血流动力学变化。这些观察结果表明,皮质间质区为肾内细胞间信号传导提供了一个潜在的重要区域。